Gossamer Bio Announces Pricing of Initial Public Offering

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of?$16.00?per share. The shares are expected to begin trading on the Nasdaq Global Select Market on?February 8, 2019?under the t